Tinzaparin (Innohep)
Jump to navigation
Jump to search
Withdrawn from US market in 2011
General information
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 2000-07-14: Initial FDA approval: treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with Warfarin (Coumadin)
- 2011-02-10: Voluntary recall as a voluntary measure after a dialogue with the FDA following an inspection at the production facility in Ballerup, Denmark. The dialogue concerned the production process and more specifically, the theoretical risk of presence of particulate matter in the released vials.
- 2011: Withdrawn from US market. "LEO Pharma discontinued marketing all Innohep presentations after the recall due to low usage of the products in the US."
Also known as
- Brand name: Innohep, Tinprin